drugset / Trial / NCT06727630
A Phase Ib Study of PRJ1-3024 for Treatment of Advanced or Metastatic Melanoma
NaSingle-groupOpen-labelTreatment
Summary
This is a Phase Ib, open-label study to determine the safety and preliminary efficacy of PRJ1-3024 in China subjects with unresectable local advanced or metastatic melanoma
Timeline
- Start
- 2024-03-14
- Primary completion
- 2025-04-30
- Completion
- 2025-10-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PRJ1-3024 | Small molecule | 300 mg | Oral |